Eloxx Pharmaceuticals Inc (OTCPK:ELOX)
$ 0.655 -0.085 (-11.49%) Market Cap: 2.06 Mil Enterprise Value: 3.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Q4 2018 Eloxx Pharmaceuticals Inc Earnings Call Transcript

Mar 08, 2019 / 01:00PM GMT
Release Date Price: $470.4 (+1.55%)
Operator

Good morning, everyone, and welcome to Eloxx Pharmaceuticals' Fourth Quarter and Full Year 2018 Earnings Webcast and Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Barbara Ryan, Eloxx' Investor Relations Officer. Please begin.

Barbara Ryan
Eloxx Pharmaceuticals, Inc. - IR Officer

Welcome, and thank you for joining us this morning for a review of Eloxx Pharmaceuticals' fourth quarter and full year 2018's financial results and business update.

Joining me this morning are Robert Ward, Chairman and Chief Executive Officer of Eloxx Pharmaceuticals; Dr. Greg Williams, our Chief Operating Officer; David Snow, our Chief Business Officer; Greg Weaver, Chief Financial Officer; and Dr. Matthew Goddeeris, Director of Research.

Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot